Jordi Gratacós

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

Peter Nash, Bruce Kirkham, Masato Okada et al. · The Lancet · 2017 · 390 citations · Full text

Rheumatoid Disorder, Rheumatology, Spirit-p2 Phase 3 +12

SERUM CYTOKINES (IL-6, TNF-α, IL-1β AND IFN-γ) IN ANKYLOSING SPONDYLITIS: A CLOSE CORRELATION BETWEEN SERUM IL-6 AND DISEASE ACTIVITY AND SEVERITY

Jordi Gratacós, A. Collado, Xavier Filella et al. · Lara D. Veeken · 1994 · 332 citations

Immunology, Tnf-alpha Serum Levels, Inflammation +20

Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial

Iain B. McInnes, Frank Behrens, Philip J. Mease et al. · The Lancet · 2020 · 271 citations · Full text

Rheumatology, Autoimmune Disease, Medicine +10

Disease pattern of spondyloarthropathies in Spain: description of the first national registry (REGISPONSER) extended report

Pedro Zarco, Eduardo Muñóz, Xavier Juanola et al. · Lara D. Veeken · 2007 · 190 citations · Full text

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

Atul Deodhar, Alice B. Gottlieb, Wolf‐­Henning Boehncke et al. · The Lancet · 2018 · 181 citations

Rheumatology, Medicine, Systemic Treatment +9